MustGrow Announces Record Q3-2025 Results
MWN-AI** Summary
MustGrow Biologics Corp. (TSXV: MGRO), a prominent player in the biological and regenerative agriculture sector, has announced a strong performance for the third quarter of 2025, highlighting record results and a marked increase in sales revenue. The company is set to host an investor webcast on November 26, 2025, at 4:00 PM ET, where management will discuss these results in detail.
For Q3-2025, MustGrow reported sales revenue of $0.8 million, a significant increase from the previous year's zero revenue during the same quarter. The gross profit for the period was $180,555, yielding a gross profit margin of 22.9%, which represented an improvement from 20.9% in Q2-2025. The company's cash and equivalents stood at $3.3 million, complemented by $1.9 million in inventory as of September 30, 2025.
Corey Giasson, President and CEO, emphasized that the third quarter generally represents a slower season in the agricultural calendar due to the harvesting period. He expressed confidence in a stronger finish for Q4 and anticipates robust sales in Q1-2026 as farmers prepare for the growing season. This forward outlook aligns with MustGrow's strategy to enhance both its NexusBioAg Canadian distribution and its TerraSante biofertility products in the U.S.
The webcast will provide a platform for investors to pose questions, which can be submitted in advance via email. Interested parties are encouraged to register at least five minutes before the event for optimal participation.
As MustGrow prepares for future growth, the company's commitment to sustainability and its extensive portfolio of innovative agricultural solutions continues to position it for success in a changing market landscape. For more information, visit MustGrow's official website.
MWN-AI** Analysis
MustGrow Biologics Corp. (TSXV: MGRO) has reported promising results for Q3 2025, showcasing significant sales revenue growth—recording $0.8 million compared to none in the same period last year. This indicates a successful implementation of their strategy to penetrate the market for biological and regenerative agricultural solutions. The improvement in gross profit margin to 22.9% suggests that MustGrow is optimizing its product mix and enhancing operational efficiencies.
Given the cyclical nature of agricultural input purchasing behavior, it is important to note that Q3 is typically a low revenue season due to farmers focused on harvest, and sales are expected to spike in Q4 and Q1 2026 as growers prepare for the planting season. Investors should anticipate a strong finish to the year, driven by the company’s NexusBioAg distribution efforts, which will likely amplify as the upcoming growing season approaches.
With cash reserves at $3.3 million and a committed focus on expanding sales through its proprietary and third-party product lines, MustGrow is well-positioned to capitalize on upcoming opportunities. Additionally, the company’s ongoing collaborations, such as its partnership with Bayer AG, highlight its commitment to global expansion and commercialization of its innovative technologies.
For investors, MustGrow is an intriguing option within the sustainable agriculture sector, especially with its increasing product offerings that replace restricted synthetic chemicals. The upcoming investor webcast offers a valuable opportunity for stakeholders to engage with MustGrow’s leadership and gain insights into the company’s future plans and growth strategies.
As the market trends toward sustainable farming solutions, MustGrow’s trajectory appears positive, making it a stock to consider for growth-centric portfolios focusing on environmentally-friendly agricultural innovations.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Investor Webcast: Wednesday, November 26th at 4:00pm ET / 1:00pm PT.
Register/View Here: https://us02web.zoom.us/webinar/register/8617635107958/WN_Ka6aNlTZTLuCJPaetQoLuQ.
Please join/register at least 5 minutes prior to the call.
Questions emailed to info@mustgrow.ca will be addressed during the Q&A portion of the webcast.
Saskatoon, Saskatchewan--(Newsfile Corp. - November 25, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended September 30, 2025. For complete details, please refer to the Q3-2025 Condensed Interim Financial Statements and associated Management's Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company's website: www.mustgrow.ca.
Key Financial Highlights:
- Sales revenue of $0.8 million was recorded in Q3-2025 vs. no revenue in Q3-2024
- Gross profit of $180,555 equating to a 22.9% gross profit margin in Q3-2025 (up from 20.9% in Q2-2025)(1)
- Cash and equivalents on hand as at September 30, 2025 was $3.3 million with inventory of $1.9 million
"The third calendar quarter is typically the lowest product revenue 'shoulder season' for Canadian agriculture as farmers are harvesting their crops rather than purchasing input products. MustGrow's gross profit margin improvement over the second quarter resulted from higher margin product sales through our Canadian sales and distribution division, NexusBioAg," stated Corey Giasson, President and CEO of MustGrow. "As mentioned in previous earnings calls, Q1 and Q4 are traditionally stronger sales periods, as Canadian farmers purchase crop inputs. We are looking forward to a strong finish to the year in Q4 and also Q1-2026 as farmers purchase products in preparation for the 2026 growing season."
The Company continues to focus on capital allocation that generates revenue growth of both its NexusBioAg Canadian sales and distribution business and TerraSanteTM biofertility product sales in the U.S.
Notes:
1) Gross margin is a non-IFRS financial measure. This ratio expresses gross profit as a percentage of revenue for a given period. It assists in explaining the Company's results from period to period and measuring profitability. This ratio is calculated by dividing gross profit for a period by the corresponding revenue for the period. There is no directly comparable IFRS measure.
About MustGrow
MustGrow Biologics Corp. is a fully-integrated provider of innovative biological and regenerative agriculture solutions designed to support sustainable farming. The Company's proprietary and third-party product lines offer eco-friendly alternatives to restricted or banned synthetic chemicals and fertilizers. In North America, MustGrow offers a portfolio of third-party crop nutrition solutions, including micronutrients, nitrogen stabilizers, biostimulants, adjuvants and foliar products. These products are synergistically distributed alongside MustGrow's wholly-owned proprietary products and technologies that are derived from mustard and developed into organic biocontrol and biofertility products to help replace banned or restricted synthetic chemicals and fertilizers. Outside of North America, MustGrow is focused on collaborating with agriculture companies, such as Bayer AG in Europe, the Middle East and Africa, to commercialize MustGrow's wholly-owned proprietary products and technologies. The Company is dedicated to driving shareholder value through the commercialization and expansion of its intellectual property portfolio of approximately 109 patents that are currently issued and pending, and the sales and distribution of its proprietary and third-party product lines through NexusBioAg. MustGrow is a publicly traded company (TSXV-MGRO) and has approximately 58.9 million common shares issued and outstanding and 69.1 million shares fully diluted. For further details, please visit www.mustgrow.ca.
Contact Information
Corey Giasson
Director & CEO
Phone: +1-306-668-2652
info@mustgrow.ca
MustGrow's Forward-Looking Statements
Certain statements included in this news release constitute "forward-looking statements" which involve known and unknown risks, uncertainties and other factors that may affect the results, performance or achievements of MustGrow.
Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", "is expected", "budget", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "occur" or "be achieved". Forward-looking statements are subject to a number of risks and uncertainties that may cause the actual results of MustGrow to differ materially from those discussed in such forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, MustGrow. Important factors that could cause MustGrow's actual results and financial condition to differ materially from those indicated in the forward-looking statements include: those risks described in more detail in MustGrow's Annual Information Form for the year ended December 31, 2024 and other continuous disclosure documents filed by MustGrow with the applicable securities regulatory authorities which are available on SEDAR+ at www.sedarplus.ca. Readers are referred to such documents for more detailed information about MustGrow, which is subject to the qualifications, assumptions and notes set forth therein.
Neither the TSX Venture Exchange, nor their Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTC Markets has approved the contents of this release or accepts responsibility for the adequacy or accuracy of this release.
© 2025 MustGrow Biologics Corp. All rights reserved.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275899
FAQ**
Can you elaborate on the specific strategies MustGrow Biologics Corp. is implementing to drive revenue growth in both the NexusBioAg division and TerraSante biofertility product sales in the U.S. market?
Given the gross profit margin improvement in Q3-2025, what key factors contributed to this increase, and how does MustGrow plan to maintain or enhance these margins going forward?
What are the company's expectations for Q4-2025 and Q1-2026 sales, and how do these expectations align with the historical patterns of sales in Canadian agriculture?
How does MustGrow Biologics Corp. prioritize its patent portfolio of approximately 109 patents in terms of commercialization and impact on overall shareholder value?
**MWN-AI FAQ is based on asking OpenAI questions about MustGrow Biologics Corp (OTC: MGROF).
NASDAQ: MGROF
MGROF Trading
0.0% G/L:
$0.3897 Last:
645 Volume:
$0.3897 Open:
